Organization · Venture Capital
Biovance Capital
Biovance Capital is a Lisbon-based venture capital firm focused on early-stage biopharma investments across Europe, particularly in Southern Europe. The firm aims to support the development of transformative therapies in various therapeutic areas.
Overview
What Biovance Capital does
What Biovance Capital is
Biovance Capital is a Lisbon-based venture capital firm focused on early-stage biopharma investments across Europe, particularly in Southern Europe. The firm aims to support the development of transformative therapies in various therapeutic areas.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2023
- Approximate age
- About 3 years
- Structured capabilities
- Funder
- Last reviewed
- April 10, 2026
Official channels
Find Biovance Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
Biovance Capital as a funder
Investment thesis
Biovance Capital focuses on early-stage biopharma companies in Southern Europe, aiming to support the development of transformative therapies with robust preclinical models and patented assets.
Focus narrative
Biovance Capital primarily invests in seed and Series A rounds of early-stage biopharma companies. The firm targets companies developing therapeutics with strong preclinical models and patented or patentable assets. It emphasizes sectors with potential for venture capital, mergers and acquisitions, or initial public offerings, ensuring a favorable regulatory environment and reimbursement policies.
Value beyond capital
Biovance Capital adds value to its portfolio companies through its extensive network in the biopharma sector, access to research institutions, and expertise in navigating regulatory pathways. The team comprises experienced professionals with backgrounds in biomedical science and medicine, enhancing their ability to support portfolio companies in achieving their development goals.
Terms and economics
- Typical check
- $1,500,000–$6,000,000
Focus and fit
- Stages
- Seed · Series A
- Regions
- Europe
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 1
Portfolio context
Biovance Capital's inaugural investment is in Mondego Bio, a Portuguese oncology startup focused on innovative cancer treatments. The firm led the Series A round alongside OrbiMed and Torrey Pines.
Common questions
What to know about Biovance Capital
Upseed classifies Biovance Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 10, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.